The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Falk Foundation; Lilly; Merck Serono; Merck Serono; MSD; Nordic Bioscience; Pfizer; Pfizer; Roche; Roche
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); European Organisation for Research and Treatment of Cancer (EORTC) (Inst); Merck Serono (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Roche
A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
 
Rui-hua Xu
No Relationships to Disclose
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Crystal S. Denlinger
Honoraria - Dava Oncology
Consulting or Advisory Role - Bayer; BeiGene; Bristol-Myers Squibb; Lilly; Merck
Research Funding - Advaxis (Inst); Agios (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merrimack (Inst); OncoMed (Inst)
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences
 
Jin Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Jiang Li
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Henry Castro
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Markus Hermann Moehler
No Relationships to Disclose